Quarterly ResultMay 14, 2026, 03:08 PM
MIRA Pharmaceuticals Q1 Net Loss Narrows to $1.15M; Going Concern Doubt
AI Summary
MIRA Pharmaceuticals reported a net loss of $1.15 million for the first quarter of 2026, an improvement from $1.78 million in the same period last year, with basic and diluted loss per share narrowing to $0.03. The company's cash balance decreased to $4.82 million from $6.35 million at the end of 2025. Management expressed substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
Key Highlights
- Net loss for Q1 2026 narrowed to $1.15 million from $1.78 million in Q1 2025.
- Basic and diluted loss per share improved to $0.03 in Q1 2026 from $0.11 in Q1 2025.
- Cash and short-term investments totaled $9.41 million as of March 31, 2026.
- Cash used in operating activities decreased to $1.20 million from $1.63 million year-over-year.
- General and administrative expenses significantly decreased to $0.58 million from $1.49 million.
- Research and development expenses increased to $0.52 million from $0.31 million.
- Company faces substantial doubt about its ability to continue as a going concern.